Lipkin's Monster ME/CFS Study: Microbes, Immunity & Big Data
The Microbe Discovery Project outlines an ambitious new study by top researchers that has collected patient samples, but needs desperately funds to complete the work.
Discuss the article on the Forums.

Hemispherx reports approval of Ampligen for ME/CFS in Argentina.

Discussion in 'General ME/CFS News' started by medfeb, Aug 23, 2016.

  1. medfeb

    medfeb Senior Member

    Messages:
    470
    Likes:
    1,853
    This approval is for the severe form of ME/CFS. Note that this does not automatically translate to approval in the United States or to other countries. They also need to work through "manufacturing site inspections and reimbursement evaluation by the Health Services Authority (SSS), the central health authority in Argentina."

    An extract of the article is below. The full article includes additional details.

    http://www.globenewswire.com/news-r...of-Myalgic-Encephalomyelitis-Chronic-Fat.html

    First Product Approved for ME/CFS Indication Anywhere in the World

    Breakthrough Approval Provides Clear Path for Growth in Latin America and the European Union

    PHILADELPHIA, Aug. 23, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”), announced that it has received approval of its New Drug Application (NDA) from Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica (ANMAT) for commercial sale of rintatolimod (U.S. tradename: Ampligen®) in the Argentine Republic for the treatment of severe myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). The product will be marketed by GP Pharm, Hemispherx’s commercial partner in Latin America. We believe that rintatolimod is the first drug to receive approval for this indication anywhere in the world. We also believe that there are no other products in the pipeline for approval, worldwide, for this debilitating disease...

    The approval was based on submission of two pivotal studies, AMP-502 and AMP-516. Safety data also included additional CFS and non-CFS studies for a total of over 800 subjects including over 100 subjects with severe CFS who received Ampligen® for one year or longer. Several post-approval activities are required to be completed before product launch, including manufacturing site inspections and reimbursement evaluation by the Health Services Authority (SSS), the central health authority in Argentina. “Working closely with our partner in this effort, GP Pharm, our team at Hemispherx addressed all medical and scientific issues presented by ANMAT and deserves great credit for this major success. At Hemispherx, we may be small by big pharma standards, but our commitment to addressing this dire unmet medical need makes us mighty,” stated Hemispherx CEO Tom Equals.

    Approval for commercial sale in Argentina provides a platform for potential commercial sales in certain countries within the European Union under regulations that support cross-border pharmaceutical sales of licensed drugs. Hemispherx and GP Pharm are now working to expand the approval of rintatolimod to additional countries with a focus on Latin America. In Europe, approval in a country with a stringent regulatory process in place, such as Argentina, adds further validation for the product as the Early Access Program (EAP) is launched in Europe....
     
    Last edited: Aug 23, 2016
  2. CaptainA

    CaptainA

    Messages:
    70
    Likes:
    116
    I feel like approval in other countries is just a matter of time now. Also, does anyone know of any doctors in Argentina that are interested in treating people with it? If one or two of them were to specialize in treating people with Ampligen I could guess that a fair amount of people would travel to do it.
     
  3. Never Give Up

    Never Give Up Collecting improvements, until there's a cure.

    Messages:
    956
    Likes:
    3,949
    Genetic Literacy Project has posted an article, not just the press release, on the topic.

    https://www.geneticliteracyproject....e-syndrome-mystery-disease-causes-come-focus/

    Written by, Ben Locwin, Ph.D., M.B.A., M.S. is a contributor to the Genetic Literacy Project and is an author of a wide variety of scientific articles in books and magazines. He is an expert contact for the American Association of Pharmaceutical Scientists (AAPS), a member in the American Statistical Association (ASA), and a consultant in the biological sciences, pharmaceutical, psychological industries and for academia. Follow him at @BenLocwin.

    It's written from this perspective:


    He picked out a few random bits of evidence supporting the biological origin of the difficult to pin down disease. He used the word "debilitating", but otherwise did not describe symptoms.

    He tweeted it.

    It is open for comments.
     
  4. CFS_for_19_years

    CFS_for_19_years Hoarder of biscuits

    Messages:
    2,004
    Likes:
    5,072
    USA
    This arrived in an email today from Hemispherx Biopharma:
    Biotech Update: Major Breakthrough for Hemispherx BioPharma, Inc.

    Published on Aug 25, 2016
    $HEB - SCN's Jane King sits down with CEO Thomas Equels of Hemispherx BioPharma Inc., (NYSE: HEB), and guest analyst Jeffrey Kraws of Crystal Research Associates, to discuss the biopharmaceutical company's recent drug approval.

    Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen®) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic. First Product Approved for ME/CFS Indication Anywhere in the World. Breakthrough Approval Provides Clear Path for Growth in Latin America and the European Union.

     
    Johannawj and CaptainA like this.

See more popular forum discussions.

Share This Page